Pacific GeneTech
Pacific GeneTech develops and commercializes next-generation vaccines and biologics targeting areas of high unmet need in food safety and animal health. Their proprietary platforms, Aegis and Hercules, enable broad-spectrum protection and enhanced vaccine efficacy. The company collaborates globally, licensing its vaccines and adjuvants for use in various animal species and human applications, with a focus on innovative, cost-effective solutions that contribute to food safety, reduce antibiotic resistance, and support sustainable development.
Industries
Nr. of Employees
small (1-50)
Pacific GeneTech
Products
Recombinant microbial vector vaccine platform (Aegis)
A platform that uses recombinant bacterial and yeast vectors to present conserved antigens and immunopotentiators on vector surfaces for cross-protective vaccine constructs suitable for live or inactivated formats and oral or injectable delivery.
Universal mannosylated chitosan adjuvant/delivery system (Hercules)
A modified chitosan-based adjuvant designed to enhance mucosal immunity, direct antigens to antigen-presenting cells, and improve efficacy of orally and injectable inactivated and DNA vaccines.
Inactivated oral Eimeria (coccidiosis) vaccine for poultry
An inactivated oral vaccine formulation for multiple Eimeria species administered via spray or drinking water, developed using a recombinant vector platform with an adjuvant delivery system; positioned as a cross-protective alternative to live oocyst vaccines.
Oral cross-protective enteric vaccine for swine (Salmonella / E. coli)
A live attenuated oral vaccine based on a conserved antigen to provide cross-protection against Salmonella and pathogenic E. coli strains, evaluated for reduction of fecal shedding and improvement in growth performance.
Recombinant microbial vector vaccine platform (Aegis)
A platform that uses recombinant bacterial and yeast vectors to present conserved antigens and immunopotentiators on vector surfaces for cross-protective vaccine constructs suitable for live or inactivated formats and oral or injectable delivery.
Universal mannosylated chitosan adjuvant/delivery system (Hercules)
A modified chitosan-based adjuvant designed to enhance mucosal immunity, direct antigens to antigen-presenting cells, and improve efficacy of orally and injectable inactivated and DNA vaccines.
Inactivated oral Eimeria (coccidiosis) vaccine for poultry
An inactivated oral vaccine formulation for multiple Eimeria species administered via spray or drinking water, developed using a recombinant vector platform with an adjuvant delivery system; positioned as a cross-protective alternative to live oocyst vaccines.
Oral cross-protective enteric vaccine for swine (Salmonella / E. coli)
A live attenuated oral vaccine based on a conserved antigen to provide cross-protection against Salmonella and pathogenic E. coli strains, evaluated for reduction of fecal shedding and improvement in growth performance.
Services
Out-licensing and commercialization agreements
Licensing vaccine and adjuvant technology to global and regional partners for scale-up, registration and distribution.
Adjuvant manufacturing and supply via joint ventures
Regional manufacturing and supply of adjuvant material through joint-venture manufacturing partnerships to serve local markets.
R&D collaborations and translational development
Collaborative discovery and translational programs with universities and industry partners to advance vaccine candidates from discovery to preclinical proof-of-concept.
Out-licensing and commercialization agreements
Licensing vaccine and adjuvant technology to global and regional partners for scale-up, registration and distribution.
Adjuvant manufacturing and supply via joint ventures
Regional manufacturing and supply of adjuvant material through joint-venture manufacturing partnerships to serve local markets.
R&D collaborations and translational development
Collaborative discovery and translational programs with universities and industry partners to advance vaccine candidates from discovery to preclinical proof-of-concept.
Expertise Areas
- Vaccine research and development
- Adjuvant formulation and mucosal immunity
- Preclinical animal trial design and execution
- Bioprocessing and fermentation manufacturing
Key Technologies
- Recombinant bacterial vectors
- Yeast expression vectors
- Mannosylated chitosan adjuvant
- Oral/nasal vaccine delivery